About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Breast Cancer Clinical Trials | 16,743 Studies Recruiting

Clinical TrialsBreast Cancer

Breast Cancer Clinical Trials

Browse 16,743 clinical trials for breast cancer. Find studies that match your criteria and connect with research centers.

Find trials near:

New York Los Angeles Chicago Houston Phoenix Philadelphia

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 2881-2900 of 16,743 trials

UnknownInvestigation of Gene Mutations in Patients With Triple-negative and Patients With HER2+ Breast Cancer AdenocarcinomaThe present study is a transnational study in patients with high risk recurrent breast cancer who receive adjuvant chemotherapy with epirubicin and cyclophosphamide followed by…NCT04365790·Athens WithdrawnTaxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast CancerThe primary purpose of this research study is to see whether adding bavituximab (an investigational drug) to the standard chemotherapy drug taxane, will improve the results of the…NCT02651610·Bakersfield, California and 1 other Active not recruitingDNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, Estrogen Receptor positive, HER-2 negative breast cancer (DARE)NCT04567420·Tucson, Arizona and 18 others

Related Searches

breast carcinomatrials

Data from ClinicalTrials.govTerms

UnknownBreast Cancer Margin Delineation Using Polarization Subtraction Imaging TechnologyThis study will evaluate LumaScan, an innovative polarization microscope for real time, intraoperative imaging and evaluation of the surface of excised tissue excised during…NCT02207179·Madison, Wisconsin

CompletedThe Impact of the Gene Recurrence Score on Chemotherapy Prescribing in ER Positive, Lymph Node Positive Early Stage Breast CancerThis study examines the impact of an additional tumour test called the 21 gene Recurrence Score (OncotypeDx®), a commercially available test on a Medical Oncologist's decision to…NCT03843346·Letterkenny, Co. Donegal and 9 others

RecruitingSHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem CellsThe clinical trial is a phase 1, single-arm trial that will evaluate the safety of the investigational treatment on metastatic pancreatic cancer and metastatic breast cancer.NCT04150042·Boston, Massachusetts and 1 other

RecruitingSRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain MetastasesThis is a single arm study of abemaciclib and endocrine therapy with stereotactic radiosurgery (SRS) among patients with hormone receptor (HR)+/HER2- metastatic breast cancer…NCT04923542·Tampa, Florida and 1 other

CompletedNeo-Adjuvant Study in Triple Negative Breast Cancer PatientsIxabepilone and capecitabine combination has demonstrated to be an active regimen in patients with metastatic breast cancer after failing other treatments.NCT01097642·Houston, Texas

CompletedMemory and Attention Adaptation Training-Geriatrics (MAAT-G)Cancer-related cognitive dysfunction (CRCD) affects up to 75% of patients receiving chemotherapy and older adults are at greater risk of developing CRCD, which can negatively…NCT04230941·Rochester, New York

RecruitingData Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton TherapyThis study collects information on the side effects of proton therapy and detailed information on the proton therapy treatment plan itself.NCT00991094·Houston, Texas

UnknownIntercostobrachial Nerve Sparing to Reduce Post-Surgical PainSacrifice of the intercostobrachial nerve (ICBN) during surgery is associated with development of persistent post-surgical pain (PPSP), which affects up to 60% of breast cancer…NCT03421522·Hamilton, Ontario

UnknownEfficacy and Safety Of Xeloda as Sequential Adjuvant Therapy After Chemotherapy in Breast CancerSelect 600 cases of women with breast cancer of triple negative or Her-2 positive or with more than 4 axillary lymph node metastasis.NCT01662128·Tianjin, Tianjin Municipality

CompletedCorrelation Between Circulating Tumor Cells and Brain Disease Control After Focal Radiotherapy for Metastases of Breast CancerThis study assesses the number of CTCs before and 4-5 weeks after focal stereotactic radiotherapy, in single or fractionated dose, and correlate with the local and distant brain…NCT02941536·São Paulo, São Paulo

WithdrawnPlasma Circulating Tumor DNA Analyses in ER+ Metastatic Breast CancerThe purpose of this study is to evaluate whether increased mutant ESR1 allele fraction in plasma ctDNA 3-6 weeks after initiating salvage endocrine therapy is predictive of…NCT03161834·Chapel Hill, North Carolina

UnknownNivolumab and Eribulin in HER2 Negative Metastatic Breast CancerCancer therapeutics such as chemotherapy may modulate tumor/immune-system interactions in favor of the immune system.NCT04061863·Seongnam

RecruitingPHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast CancerPHOENIX is a window of opportunity (WOP), open-label, multi-centre, phase IIa trial comprising multiple non-comparative treatment cohorts with patient allocation via minimisation…NCT03740893·Bournemouth, Dorset and 5 others

UnknownNeoadjuvant Inetetamab Combined With Pertuzumab and Paclitaxel/Carboplatin for Breast CancerInetetamab (Cipterbin) is a newly marketed anti-HER2 monoclonal antibody with amino acid modified Fc region and enhanced antibody-dependent cellular cytotoxicity (ADCC) effect.NCT05749016·Beijing

UnknownRelationship Between Hypoxia and Endocrine Response in Human Breast CancerThe aim of our current study was to analyze whether 18F-labeled Fluoromisonidazole (1-(2-nitro-1-imidazolyl)- 2-hydroxy-3-fluoropropane \[18F-FMISO\]) PET/CT and expression of…NCT01814449·Shanghai, Shanghai Municipality

CompletedEfficacy and Optimal Dose Selection of Intranasal Dexmedetomidine During Breast Lumpectomy Under Local AnaesthesiaThis trial is going to evaluate the safety and effectiveness of intranasal DEX(dexmedetomidine) in breast lumpectomy under local anaesthesia,and to investigate the optimal dose of…NCT02675049

Enrolling by invitationBreast Cancer PET/CT Imaging With 68Ga-pAKTiAbnormal activation of the PI3K-AKT signaling pathway in breast cancer patients is closely associated with tumor progression.NCT06943313·Shanghai

PreviousPage 145 of 838Next